Arena favors discretion over valor with Belviq in EU
This article was originally published in Scrip
Arena Pharmaceuticals has withdrawn its EU marketing application for Belviq (lorcaserin HCl) with a view to a later refiling, in the latest regulatory hiccup for the new wave of obesity treatments. The markets were not impressed, sending Arena's share price down to $8.21 during trading on Nasdaq on 2 May, but it later rallied to close up by 2.1% at $8.40.
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.